Select Page
Heart failure with preserved ejection fraction(HFpEF) impacts millions of patients in the US, with its prevalence continuing to increase as an emerging complication of metabolic syndrome and our obesity epidemic. Nearly half of all patients with heart failure worldwide have HFpEF, and yet there continues to be no effective proven treatment for these patients. All therapies targeting HFpEF have failed in this population. This is an incredibly active area of bench to bedside research, given the enormous impact that an effective therapy could have. With that, we’re thrilled to welcome two speakers who will discuss translational approaches to understanding a complex disease. Dr. Sanjiv Shah will discuss data-driven approaches to address the heterogeneity of HFpEF phenotypes, and Dr. Barry Borlaug will discuss HFpEF and the hemodynamics of heart failure, as part of our Bench-to-Bedside Grand Rounds series.

Department of Medicine Grand Rounds
December 15, 2020

2:45
HFpEF and the hemodynamics of heart failure?
Barry Borlaug, MD
Professor of Medicine
Director, Circulatory Failure Research, Division of Cardiovascular Diseases
Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine
Mayo Clinic, Rochester, Minnesota

28:05
Data-Driven Approaches to Resolving the Heterogeneity of Heart Failure with Preserved Ejection Fraction
Sanjiv Shah, MD
Director, Institute for Augmented Intelligence in Medicine –
Center for Deep Phenotyping and Precision Therapeutics
Director, Northwestern Heart Failure with Preserved Ejection Fraction Program
Stone Endowed Professor of Medicine (Cardiology)
Northwestern University Feinberg School of Medicine

View Presentations  |  CME Module